Skip to main content
Caplight Logo









Trace Neuroscience

Trace Neuroscience

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.traceneuro.com/

Last Round

Series A

Nov 12, 2024

Total Funding Raised

$101M

Company Overview

Trace Neuroscience is a biopharmaceutical company developing novel genomic therapies to restore UNC13A protein function for the treatment of amyotrophic lateral sclerosis (ALS).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologygenetic medicineRNA therapeuticsneurodegenerative diseasedrug discoveryamyotrophic lateral sclerosisALSRNA regulationantisense oligonucleotidesASObiotech startupclinical-stage biotechtherapeutic platformdrug developmentbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trace Neuroscience Comparables

Compare Trace Neuroscience with similar companies based on industry and business-model similarity.

Trace Neuroscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Harness Therapeutics
86%
AcuraStem
86%
NuCyRNA Therapeutics
86%

Trace Neuroscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 12, 2024

Key People

Founding team and executive leadership

Megan Baierlein

Chief Operating Officer

Executive Team

Irina Antonijevic

Chief Medical Officer

Executive Team

Trace Neuroscience Investors

Notable investors and investment history

Trace Neuroscience investors
InvestorRounds
RA Capital ManagementSeries A
GVSeries A
Atlas VentureSeries A
Third Rock VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    Developing medicines to restore UNC13A gene function for nerve-muscle communication.

  • Nov 12, 2024

    $101M round led by Third Rock Ventures

Trace Neuroscience Filings

Explore SEC and related filing metadata, where available.

Trace Neuroscience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Trace Neuroscience's valuation, stock price, and market status.

Is Trace Neuroscience a public or private company?

Trace Neuroscience is a private company.

What is the current stock price of Trace Neuroscience?

Trace Neuroscience is a private company with no public stock price. No recent secondary market data is available.

How much is Trace Neuroscience worth (valuation)?

Valuation information for Trace Neuroscience is not publicly available.

Can I buy Trace Neuroscience stock?

Trace Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Trace Neuroscience's last funding round?

Trace Neuroscience's most recent funding round was Series A on November 12, 2024.

Who are the main investors in Trace Neuroscience?

Key investors in Trace Neuroscience include Third Rock Ventures.

Will Trace Neuroscience IPO soon?

No public IPO plans have been announced for Trace Neuroscience.

How can I track Trace Neuroscience secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Trace Neuroscience's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range18
Year Founded2024
Last FundingNov 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?